Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.36 |
| ▸ | KDM1A | O60341 | 10/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2836576 | 0.79 | ENPP1 (0.39) | ENPP1PDGFRBKDM1AEGFRPDE3A | |
| SCHEMBL2833438 | 0.77 | P2RX7 (0.43) | ENPP1PDGFRBKDM1AEGFRPDE3A | |
| SCHEMBL10012042 | 0.76 | ENPP1 (0.39) | ENPP1KDM1AEGFRPDE3A | |
| SCHEMBL2837582 | 0.76 | EGFR (0.42) | ENPP1KDM1AEGFRRET | |
| SCHEMBL2830929 | 0.72 | ABCG2 (0.44) | ENPP1PDGFRBEGFR | |
| SCHEMBL2836613 | 0.71 | EGFR (0.39) | ENPP1EGFRRET | |
| SCHEMBL2836110 | 0.69 | P2RX7 (0.44) | ENPP1EGFR | |
| SCHEMBL10012996 | 0.68 | ENPP1 (0.37) | ENPP1EGFR | |
| SCHEMBL2832536 | 0.67 | RET (0.43) | ENPP1EGFRAURKARET | |
| SCHEMBL2833476 | 0.67 | EGFR (0.39) | EGFRRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261740-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | NATCO PHARMA LIMITED (IN) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261740-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | MKI67, CDKL5, CCNI | ENPP1 2397/4885PDGFRB 1261/4885KDM1A 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.